Island Pharmaceuticals kicks off "critical" study in Dengue fight
Published: 12:03 24 Nov 2023 AEDT
Island Pharmaceuticals Ltd (ASX:ILA), a leader in antiviral drug development, has initiated the first cohort dosing in its single ascending dose (SAD) study for its lead asset ISLA-101, aimed at preventing and treating dengue and other mosquito-borne diseases.
The primary objective is to determine the safety of ISLA-101 at various concentrations and to ascertain its efficacy in achieving blood levels predicted to be effective against the dengue virus.
Looking ahead, the data readout from the SAD study is anticipated in early next year, offering valuable insights into the drug's potential and guiding future clinical strategies.
"Critical step"
Island CEO Dr David Foster said: “We are delighted to see the start of this study with the dosing of our first subject.
"This news represents a critical step in our journey towards our PEACH clinical trial, and progressing ISLA-101 toward approval as a much-needed treatment for dengue fever and other mosquito borne diseases.”
Study highlights
The SAD study is being run at Scientia Clinical Research’s clinical trial facilities in Sydney (NSW), Australia, by Contract Research Organisation, Beyond Drug Development.
The study is a dose escalation trial involving three cohorts of healthy subjects who will receive progressively increasing doses of ISLA-101.
This early-stage research is critical for establishing a safe dosing protocol and paves the way for the subsequent Phase 2a PEACH clinical trial.
About Island Pharmaceuticals
Island Pharmaceuticals is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases.
The company's lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.
